In vivo vitiligo induction and therapy model: double-blind, randomized clinical trial.

PubWeight™: 1.50‹?› | Rank: Top 4%

🔗 View Article (PMID 21982055)

Published in Pigment Cell Melanoma Res on November 02, 2011

Authors

Nanja van Geel1, Reinhart Speeckaert, Ilse Mollet, Sofie De Schepper, Julie De Wolf, Esther P M Tjin, Rosalie M Luiten, Jo Lambert, Lieve Brochez

Author Affiliations

1: Department of Dermatology, Ghent University Hospital, De Pintelaan, Ghent, Belgium. Nanja.vangeel@UGent.be

Articles by these authors

Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. J Exp Med (2006) 4.84

Clinical practice. Dysplastic nevi. N Engl J Med (2003) 2.99

Germline loss-of-function mutations in SPRED1 cause a neurofibromatosis 1-like phenotype. Nat Genet (2007) 2.55

Variant of TYR and autoimmunity susceptibility loci in generalized vitiligo. N Engl J Med (2010) 2.47

Genome-wide association analyses identify 13 new susceptibility loci for generalized vitiligo. Nat Genet (2012) 1.81

Skin-depigmenting agent monobenzone induces potent T-cell autoimmunity toward pigmented cells by tyrosinase haptenation and melanosome autophagy. J Invest Dermatol (2011) 1.71

Human squamous cell carcinomas evade the immune response by down-regulation of vascular E-selectin and recruitment of regulatory T cells. J Exp Med (2008) 1.67

Effect of the secretory small GTPase Rab27B on breast cancer growth, invasion, and metastasis. J Natl Cancer Inst (2010) 1.65

Telomerase levels control the lifespan of human T lymphocytes. Blood (2003) 1.59

Autoimmune destruction of skin melanocytes by perilesional T cells from vitiligo patients. J Invest Dermatol (2009) 1.56

The quest for the mechanism of melanin transfer. Traffic (2006) 1.53

Rab7 and Rab27a control two motor protein activities involved in melanosomal transport. Pigment Cell Res (2006) 1.39

Acute generalized exanthematous pustulosis: an overview of the clinical, immunological and diagnostic concepts. Eur J Dermatol (2010) 1.36

Molecular dissection of isolated disease features in mosaic neurofibromatosis type 1. Am J Hum Genet (2007) 1.33

EGFR in melanoma: clinical significance and potential therapeutic target. J Cutan Pathol (2011) 1.32

Autoimmune etiology of generalized vitiligo. Curr Dir Autoimmun (2008) 1.31

Comprehensive NF1 screening on cultured Schwann cells from neurofibromas. Hum Mutat (2006) 1.29

Griscelli syndrome: a model system to study vesicular trafficking. Pigment Cell Melanoma Res (2009) 1.27

Common variants in FOXP1 are associated with generalized vitiligo. Nat Genet (2010) 1.25

Comprehensive association analysis of candidate genes for generalized vitiligo supports XBP1, FOXP3, and TSLP. J Invest Dermatol (2010) 1.14

Therapeutic implications of autoimmune vitiligo T cells. Autoimmun Rev (2006) 1.12

Genome-wide analysis identifies a quantitative trait locus in the MHC class II region associated with generalized vitiligo age of onset. J Invest Dermatol (2011) 1.08

Rab27b is up-regulated in human Griscelli syndrome type II melanocytes and linked to the actin cytoskeleton via exon F-Myosin Va transcripts. Pigment Cell Res (2004) 1.08

Tumor necrosis factor receptors: biology and therapeutic potential in kidney diseases. Am J Nephrol (2012) 1.05

Pigment cell-related manifestations in neurofibromatosis type 1: an overview. Pigment Cell Res (2005) 1.01

Characterization of the molecular defects in Rab27a, caused by RAB27A missense mutations found in patients with Griscelli syndrome. J Biol Chem (2003) 1.00

Interactions of human Myosin Va isoforms, endogenously expressed in human melanocytes, are tightly regulated by the tail domain. J Invest Dermatol (2003) 0.98

Somatic loss of wild type NF1 allele in neurofibromas: Comparison of NF1 microdeletion and non-microdeletion patients. Genes Chromosomes Cancer (2006) 0.97

Management of vitiligo patients and attitude of dermatologists towards vitiligo. Eur J Dermatol (2004) 0.97

First histopathological and immunophenotypic analysis of early dynamic events in a patient with segmental vitiligo associated with halo nevi. Pigment Cell Melanoma Res (2010) 0.96

DNA methylation-based biomarkers in serum of patients with breast cancer. Mutat Res (2012) 0.96

Somatic mutation analysis in NF1 café au lait spots reveals two NF1 hits in the melanocytes. J Invest Dermatol (2007) 0.96

Haptoglobin polymorphism and infection. Adv Clin Chem (2010) 0.95

miR-145 overexpression suppresses the migration and invasion of metastatic melanoma cells. Int J Oncol (2013) 0.95

Cancer risk in immune-mediated inflammatory diseases (IMID). Mol Cancer (2013) 0.95

A case of anaphylaxis caused by macrogol 3350 after injection of a corticosteroid. Contact Dermatitis (2012) 0.95

The role of RhoC in growth and metastatic capacity of melanoma. J Cutan Pathol (2009) 0.95

The HGF/MET pathway as target for the treatment of multiple myeloma and B-cell lymphomas. Biochim Biophys Acta (2010) 0.94

Indoleamine 2,3-dioxygenase, a new prognostic marker in sentinel lymph nodes of melanoma patients. Eur J Cancer (2011) 0.93

Knockdown of myosin Va isoforms by RNAi as a tool to block melanosome transport in primary human melanocytes. J Invest Dermatol (2008) 0.92

Lipid-mediated gene delivery to the skin. Eur J Pharm Sci (2011) 0.92

T-cell immune function in tumor, skin, and peripheral blood of advanced stage melanoma patients: implications for immunotherapy. Clin Cancer Res (2011) 0.92

Monobenzone-induced depigmentation: from enzymatic blockade to autoimmunity. Pigment Cell Melanoma Res (2011) 0.92

c-Cbl is involved in Met signaling in B cells and mediates hepatocyte growth factor-induced receptor ubiquitination. J Immunol (2002) 0.92

The role of VEGF-C staining in predicting regional metastasis in melanoma. Virchows Arch (2008) 0.91

Cutis laxa of the autosomal recessive type in a consanguineous family. Eur J Dermatol (2004) 0.90

Café-au-lait spots in neurofibromatosis type 1 and in healthy control individuals: hyperpigmentation of a different kind? Arch Dermatol Res (2006) 0.90

Increased frequencies of IL-31-producing T cells are found in chronic atopic dermatitis skin. Exp Dermatol (2012) 0.89

Biological and clinical aspects of soluble transferrin receptor. Crit Rev Clin Lab Sci (2010) 0.88

Effective melanoma immunotherapy in mice by the skin-depigmenting agent monobenzone and the adjuvants imiquimod and CpG. PLoS One (2010) 0.88

T-cell avidity and tuning: the flexible connection between tolerance and autoimmunity. Int Rev Immunol (2006) 0.88

Hypomelanoses in children. J Cutan Aesthet Surg (2013) 0.87

The biology of hyperpigmentation syndromes. Pigment Cell Melanoma Res (2014) 0.87

Human telomerase reverse transcriptase-transduced human cytotoxic T cells suppress the growth of human melanoma in immunodeficient mice. Cancer Res (2004) 0.87

Different approaches for assaying melanosome transfer. Pigment Cell Res (2005) 0.86

Vitamin D binding protein: a multifunctional protein of clinical importance. Adv Clin Chem (2014) 0.86

Ipilimumab, not just another anti-cancer therapy: hypophysitis as side effect illustrated by four case-reports. Endocrine (2014) 0.86

Acanthosis nigricans in a child with mild osteochondrodysplasia and K650Q mutation in the FGFR3 gene. Am J Med Genet A (2007) 0.85

Current and emerging therapy for the management of vitiligo. Clin Cosmet Investig Dermatol (2009) 0.84

High prevalence of autoimmune thyroiditis in children and adolescents with vitiligo. Horm Res Paediatr (2013) 0.83

Koebner's phenomenon in vitiligo: European position paper. Pigment Cell Melanoma Res (2011) 0.83

Melanocyte-specific immune response in a patient with multiple regressing nevi and a history of melanoma. Anticancer Res (2011) 0.83

Transdermal penetration behaviour of drugs: CART-clustering, QSPR and selection of model compounds. Bioorg Med Chem (2007) 0.83

Clinical significance of the expression of c-Ski and SnoN, possible mediators in TGF-beta resistance, in primary cutaneous melanoma. J Dermatol Sci (2008) 0.83

ZEB2-transgene expression in the epidermis compromises the integrity of the epidermal barrier through the repression of different tight junction proteins. Cell Mol Life Sci (2014) 0.82

Efficacy of products to remove eggs of Pediculus humanus capitis (Phthiraptera: Pediculidae) from the human hair. J Med Entomol (2014) 0.82

P-cadherin counteracts myosin II-B function: implications in melanoma progression. Mol Cancer (2010) 0.81

Value and pitfalls in iodine fortification and supplementation in the 21st century. Br J Nutr (2011) 0.80

Juvenile psoriasis and its clinical management: a European expert group consensus. J Dtsch Dermatol Ges (2010) 0.80

Human epididymis protein 4 in cancer diagnostics: a promising and reliable tumor marker. Adv Clin Chem (2013) 0.80

Method to measure force required to remove Pediculus humanus capitis (Phthiraptera: Pediculidae) eggs from human hair. J Med Entomol (2005) 0.79

Biology of human pentraxin 3 (PTX3) in acute and chronic kidney disease. J Clin Immunol (2013) 0.79

A short dermoscopy training increases diagnostic performance in both inexperienced and experienced dermatologists. Australas J Dermatol (2014) 0.79

Inefficient exogenous loading of a tapasin-dependent peptide onto HLA-B*44:02 can be improved by acid treatment or fixation of target cells. Eur J Immunol (2012) 0.79

Systemic immune changes associated with adjuvant interferon-α2b-therapy in stage III melanoma patients: failure at the effector phase? Melanoma Res (2015) 0.78

Immune mediated mechanisms of melanocyte destruction: Paving the way for efficient immunotherapeutic strategies against melanoma. Oncoimmunology (2012) 0.78

Evaluation of commercially available ELISA assays as a tool for monitoring and managing pemphigus patients: a prospective study. Eur J Dermatol (2013) 0.78

Knowledge and management of scabies in general practitioners and dermatologists. Eur J Dermatol (2005) 0.78